Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cb9f654ff-kl2l2 Total loading time: 0 Render date: 2025-08-11T11:11:02.532Z Has data issue: false hasContentIssue false

Chapter 3 - Amantadine and antiglutamatergic drugs in the management of Parkinson's disease

from Section I - The Pharmacological Basis for Parkinson's Disease Treatment

Published online by Cambridge University Press:  05 March 2016

By
Marco Onofrj ,
Valerio Frazzini ,
Laura Bonanni  and
Astrid Thomas
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 13 - 22
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Joel, D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov Disord 2001; 16: 407–23.CrossRefGoogle Scholar
de la Fuente-Fernández, R, Sossi, V, Huang, Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747–54.CrossRefGoogle ScholarPubMed
Lee, JY, Lee, EK, Park, SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in disturbances in Parkinson disease. Parkinsonism Relat Disord 2009; 15: 1803–10.Google Scholar
Calabresi, P, Di Filippo, M, Ghiglieri, V, Tambasco, N, Picconi, B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9: 1106–17.CrossRefGoogle ScholarPubMed
Voon, V, Fernagut, PO, Wickens, J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140–9.CrossRefGoogle ScholarPubMed
Linazasoro, G. Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity. Clin Neuropharmacol 2009; 32: 22–7.CrossRefGoogle ScholarPubMed
Kalivas, PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10: 561–72.CrossRefGoogle ScholarPubMed
Cenci, MA, Lundblad, M. Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia. J Neurochem 2006; 99: 381–92.CrossRefGoogle ScholarPubMed
van Eimeren, T, Ballanger, B, Pellecchia, G, et al. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 2009; 34: 2758–66.CrossRefGoogle ScholarPubMed
Allers, KA, Bergstrom, DA, Ghazi, LJ, Kreiss, DS, Walters, JR. MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson's disease. Exp Neurol 2005; 191: 104–18.CrossRefGoogle Scholar
Verhagen-Metman, L, Blanchet, PJ, van den Munckhof, P, et al. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998; 13: 414–17.CrossRefGoogle ScholarPubMed
Spieker, S, Loschmann, PA, Klockgether, T. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov Disord 1999; 14: 517–19.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
Rabey, JM, Nissipeanu, P, Korczyn, AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. Neural Transm Park Dis Dement Sect 1992; 4: 277–82.CrossRefGoogle ScholarPubMed
Varanese, S, Howard, J, Di Rocco, A. NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson's disease. Mov Disord 2010; 25: 508–10.CrossRefGoogle ScholarPubMed
Iderberg, H, Rylander, D, Bimpisidis, Z, Cenci, MA. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol 2013; 250: 116–24.CrossRefGoogle ScholarPubMed
Vidal, EI, Fukushima, FB, Valle, AP, Villas Boas, PJ. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. J Am Geriatr Soc 2013; 61: 170–2.CrossRefGoogle ScholarPubMed
Hanagasi, HA, Kaptanoglu, G, Sahin, HA, Emre, M. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from l-dopa. Mov Disord 2000; 15: 1016–17.Google ScholarPubMed
Rajput, AH, Rajput, A, Lang, AE, et al. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998; 13: 851.CrossRefGoogle ScholarPubMed
Movement Disorders Society. Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov Disord 2002; 17 (Suppl. 4): S13–22.CrossRefGoogle Scholar
Crosby, NJ, Deane, KH, Clarke, CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003: CD003467.Google Scholar
Higgins, JPT, Green, S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell, 2008.CrossRefGoogle Scholar
Elahi, B, Phielipp, N, Chen, R. N-Methyl-d-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci 2012; 39: 465–72.CrossRefGoogle ScholarPubMed
Riederer, P, Kornhuber, J, Gerlach, M, et al. Glutamatergic-dopaminergic imbalance in Parkinson's disease and paranoid hallucinatory psychosis. In: Rinne, UK, Nagatsu, T, Horowski, R (eds). International Workshop Berlin: Parkinson's Disease. The Netherlands: Medicom, , 1991; 10–23.Google Scholar
Thomas, A, Iacono, D, Luciano, AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141–3.Google ScholarPubMed
Metman, LV, Del Dotto, P, LePoole, K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383–6.CrossRefGoogle ScholarPubMed
Wolf, E, Seppi, K, Katzenschlager, R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010; 25: 1357–63.CrossRefGoogle ScholarPubMed
Luginger, E, Wenning, GK, Bosch, S, Poewe, W. Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15: 873–8.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Silva-Junior, FP, Braga-Neto, P, Sueli, MF, de Bruin, VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005; 11: 449–52.CrossRefGoogle ScholarPubMed
Snow, BJ, Macdonald, L, McAuley, D, Wallis, W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. ClinNeuropharmacol 2000; 23: 82–5.Google ScholarPubMed
Verhagen, ML, Del Dotto, P, van den, Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323–6.Google Scholar
Rajput, AH, Uitti, RJ, Lang, AE, et al. Amantidine ameliorates levodopa-induced dyskinesia. Neurology 1997; 48 (Suppl. 3): A328.Google Scholar
Sawada, H, Oeda, T, Kuno, S, et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One 2010; 5: e15298.CrossRefGoogle ScholarPubMed
Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001; 58: 1660–8.CrossRefGoogle Scholar
Merello, M, Nouzeilles, MI, Cammarota, A, Leiguarda, R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22: 273–6.Google ScholarPubMed
Mukherjee, D, Patil, CG, Palestrant, D. Amantadine for severe traumatic brain injury. N Engl J Med 2012; 366: 2427.Google ScholarPubMed
Zafonte, RD, Watanabe, T, Mann, NR. Amantadine: a potential treatment for the minimally conscious state. Brain Inj 1998; 12: 617–21.CrossRefGoogle ScholarPubMed
Horiguchi, J, Inami, Y, Shoda, T. Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 1990; 13: 84–8.CrossRefGoogle Scholar
Inzelberg, R, Bonuccelli, U, Schechtman, E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006; 21: 1375–9.CrossRefGoogle ScholarPubMed
Aarsland, D, Ballard, C, Walker, Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–18.CrossRefGoogle ScholarPubMed
Ballard, C, Kahn, Z, Corbett, A. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging 2011; 28: 769–77.CrossRefGoogle ScholarPubMed
Emre, M, Tsolaki, M, Bonuccelli, U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969–77.CrossRefGoogle ScholarPubMed
Onofrj, M, Thomas, A. Acute akinesia in Parkinson disease. Neurology 2005; 64: 1162–9.CrossRefGoogle ScholarPubMed
Thomas, A, Onofrj, M. Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord 2005; 20: 1671; author reply 1671–2.CrossRefGoogle ScholarPubMed
Margetić, B, Aukst-Margetić, B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010; 19: 429–35.CrossRefGoogle ScholarPubMed
Eggert, KM, Oertel, WH, Reichmann, H (eds). Parkinson Syndrome – Diagnostik und Therapie. Leitlinien fuer Diagnostik und Therapie in der Neurologie. Berlin: Deutsche Gesellschaft fuer Neurologie, 2012.Google Scholar
Smith, EJ. Amantadine-induced psychosis in a young healthy patient. Am J Psychiatry 2008; 165: 1613.CrossRefGoogle Scholar
Harper, RW, Knothe, UC. Colored Lilliputian hallucinations with amantadine. Med J Aust 1973; 1: 444–5.CrossRefGoogle ScholarPubMed
Snoey, ER, Bessen, HA. Acute psychosis after amantadine overdose. Ann Emerg Med 1990; 19: 668–70.CrossRefGoogle ScholarPubMed
Stroe, AE, Hall, J, Amin, F. Psychotic episode related to phenylpropanolamine and amantadine in a healthy female. Gen Hosp Psychiatry 1995; 17: 457–8.CrossRefGoogle Scholar
Flaherty, JA, Bellur, SN. Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J Clin Psychiatry 1981; 42: 344–5.Google Scholar
Walsh, RA, Lang, AE. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord 2012; 27: 326.CrossRefGoogle ScholarPubMed
Riederer, P, Lange, KW, Kornhuber, J, Danielczyk, W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 1991; 338: 1022–3.CrossRefGoogle ScholarPubMed
Robles Bayón, A, Gude Sampedro, F. Inappropriate treatments for patients with cognitive decline. Neurologia 2012; 29: 523–32.CrossRefGoogle ScholarPubMed
Menendez-Gonzalez, M, Calatayud, MT, Blazquez-Menes, B. Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis 2005; 8: 289–91.CrossRefGoogle ScholarPubMed
Grant, JE, Chamberlain, SR, Odlaug, BL, Potenza, MN, Kim, SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) 2010; 212: 603–12.CrossRefGoogle ScholarPubMed
Gallini, A, Sommet, A, Salandini, AM, et al. Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease. Mov Disord 2007; 22: 1980–1.CrossRefGoogle Scholar
Sani, G, Serra, G, Kotzalidis, GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012; 26: 663–90.CrossRefGoogle Scholar
Stewart, SE, Jenike, EA, Hezel, DM, et al. 2010; A single blinded case–control study of memantine insevere obsessive-compulsive disorder. J Clin Psychopharmacol 30: 34–9.CrossRefGoogle Scholar
Pelc, I, Verbanck, P, Le Bon, O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997; 171: 73–7.CrossRefGoogle ScholarPubMed
Thomas, A, Bonanni, L, Gambi, F, Di Iorio, A, Onofrj, M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68: 400–4.CrossRefGoogle ScholarPubMed
Cera, N, Bifolchetti, S, Martinotti, G, et al. Amantadine and cognitive flexibility: decision making in Parkinson patients with severe pathological gambling and other impulse control disorders. Neuropsychiatr Dis Treat 2014; 10: 1093–101.CrossRefGoogle ScholarPubMed
Kashihara, K, Imamura, T. Amantadine may reverse punding in Parkinson's disease – observation in a patient. Mov Disord 2008; 23: 129–30.CrossRefGoogle ScholarPubMed
Pettorruso, M, Martinotti, G, Di Nicola, M, et al. Amantadine in the treatment of pathological gambling: a case report. Front Psychiatry 2012; 3: 102.CrossRefGoogle ScholarPubMed
Fasano, A, Ricciardi, L, Pettorruso, M, Bentivoglio, AR. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol 2011; 258: 656–60.CrossRefGoogle ScholarPubMed
Weintraub, D, Sohr, M, Siderowf, A, et al. Amantadine use associated with impulse control disorders in Parkinson disease. Ann Neurol 2010; 68: 963–8.CrossRefGoogle ScholarPubMed
Lee, JY, Kim, HJ, Jeon, BS. Is pathological gambling in Parkinson's disease reduced by amantadine? Ann Neurol 2011; 69: 213–14.CrossRefGoogle ScholarPubMed
Onofrj, M, Bonanni, L, Di Iorio, A, Thomas, A. Is pathological gambling in Parkinson's disease reduced by amantadine? Reply Ann Neurol 2011; 69: 214–15.CrossRefGoogle Scholar
Wang, O, Kilpatrick, RD, Critchlow, CW, et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010; 5: 182–8.CrossRefGoogle ScholarPubMed
Fahn, S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008; 23: S497–508.CrossRefGoogle ScholarPubMed
Bastiaens, J, Dorfman, BJ, Christos, PJ, Nirenberg, MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord 2013; 28: 327–33.CrossRefGoogle ScholarPubMed
Yerkes, RM, Dodson, JD. The relation of strength of stimulus to rapidity of habit-formation. J Comp Neurol Psychol 1908; 18: 459–82.CrossRefGoogle Scholar
Cools, R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1–23.CrossRefGoogle ScholarPubMed
Voon, V, Gao, J, Brezing, C, et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011; 134: 1438–46.CrossRefGoogle ScholarPubMed
Jenner, P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665–77.CrossRefGoogle ScholarPubMed
Stocchi, F, Vacca, L, Ruggieri, S, Olanow, CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62: 905–10.CrossRefGoogle ScholarPubMed
Chaudhuri, KR, Schapira, AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464–74.CrossRefGoogle Scholar
Agid, Y, Arnulf, I, Bejjani, P, et al. Parkinson's disease is a neuropsychiatric disorder. Adv Neurol 2003; 91: 365–70.Google ScholarPubMed
Onofrj, M, Bonanni, L, Manzoli, L, Thomas, A. Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. Neurology 2010; 74: 1598–606.CrossRefGoogle ScholarPubMed
Albin, RL, Dauer, WT. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis? Neurology 2012; 79: 202–3.CrossRefGoogle ScholarPubMed
Rabinak, CA, Nirenberg, MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58–63.CrossRefGoogle ScholarPubMed

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×